CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
VLPbio is developing Cervivax, an immunotherapeutic vaccine targeting cervical dysplasia and HPV-16 infections. Utilizing a proprietary platform of virus-like particles, this vaccine aims to address the unmet need for therapeutic solutions in treating cervical lesions.
VLPbio (www.vlpbio.com) is a biotechnological company applying immunotherapeutic solutionsto fight and prevent human and animal diseases addressing unmet clinical needs in the main pharmaceutical markets.
Our technology is based on patented and proprietary Ch-VLP platform (Chimeric Virus like Particles) derived from the Infectious Bursal Disease Virus (IBDV).
Virus-like particles are empty and not infectious viral particles capable of incorporating antigens involved in different pathologies in o…
VLP THE VACCINES COMPANY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
